Immunotherapy of leukemia

Evan M Hersh, J. U. Gutterman, G. M. Mavligit

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The data reviewed in this paper indicate that immunotherapy is effective in prolonging remission and survival in acute and chronic leukemia. The acute lymphocytic leukemias may or may not respond to immunotherapy and further work is needed in this area. No studies of immunotherapy in chronic lymphocytic leukemia have been done, but this will be an important area for investigation, since there is often profound immunodeficiency in this disease. The malignant lymphomas are another fertile area for this type of research, since they have a high response rate, tumor associated immunodeficiency, and at least differentiation antigens if not tumor specific antigens. The scientific basis for the use of immunotherapy in leukemia includes the demonstration of a relationship of rate and duration of remission and survival to immunocompetence, the demonstration of unique tumor associated antigens on leukemia cells, and the demonstration of immune responses to these antigens which can be boosted by immunization. At the present time, active nonspecific immunotherapy with BCG and MER and active specific immunotherapy have been proved effective in acute myelogenous leukemia. Careful attention should be given to dose schedule, route, and so forth. Other types of immunotherapy remain to be explored.

Original languageEnglish (US)
Pages (from-to)1019-1042
Number of pages24
JournalMedical Clinics of North America
Volume60
Issue number5
StatePublished - 1976
Externally publishedYes

Fingerprint

Immunotherapy
Leukemia
Active Immunotherapy
methanol extraction residue (MER) tubercle bacillus fraction
Neoplasm Antigens
Immunocompetence
Histocompatibility Antigens Class II
Differentiation Antigens
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Immunization
Lymphoma
Appointments and Schedules
Research
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hersh, E. M., Gutterman, J. U., & Mavligit, G. M. (1976). Immunotherapy of leukemia. Medical Clinics of North America, 60(5), 1019-1042.

Immunotherapy of leukemia. / Hersh, Evan M; Gutterman, J. U.; Mavligit, G. M.

In: Medical Clinics of North America, Vol. 60, No. 5, 1976, p. 1019-1042.

Research output: Contribution to journalArticle

Hersh, EM, Gutterman, JU & Mavligit, GM 1976, 'Immunotherapy of leukemia', Medical Clinics of North America, vol. 60, no. 5, pp. 1019-1042.
Hersh EM, Gutterman JU, Mavligit GM. Immunotherapy of leukemia. Medical Clinics of North America. 1976;60(5):1019-1042.
Hersh, Evan M ; Gutterman, J. U. ; Mavligit, G. M. / Immunotherapy of leukemia. In: Medical Clinics of North America. 1976 ; Vol. 60, No. 5. pp. 1019-1042.
@article{db409cc50d8744b8bc39f1002eea017b,
title = "Immunotherapy of leukemia",
abstract = "The data reviewed in this paper indicate that immunotherapy is effective in prolonging remission and survival in acute and chronic leukemia. The acute lymphocytic leukemias may or may not respond to immunotherapy and further work is needed in this area. No studies of immunotherapy in chronic lymphocytic leukemia have been done, but this will be an important area for investigation, since there is often profound immunodeficiency in this disease. The malignant lymphomas are another fertile area for this type of research, since they have a high response rate, tumor associated immunodeficiency, and at least differentiation antigens if not tumor specific antigens. The scientific basis for the use of immunotherapy in leukemia includes the demonstration of a relationship of rate and duration of remission and survival to immunocompetence, the demonstration of unique tumor associated antigens on leukemia cells, and the demonstration of immune responses to these antigens which can be boosted by immunization. At the present time, active nonspecific immunotherapy with BCG and MER and active specific immunotherapy have been proved effective in acute myelogenous leukemia. Careful attention should be given to dose schedule, route, and so forth. Other types of immunotherapy remain to be explored.",
author = "Hersh, {Evan M} and Gutterman, {J. U.} and Mavligit, {G. M.}",
year = "1976",
language = "English (US)",
volume = "60",
pages = "1019--1042",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Immunotherapy of leukemia

AU - Hersh, Evan M

AU - Gutterman, J. U.

AU - Mavligit, G. M.

PY - 1976

Y1 - 1976

N2 - The data reviewed in this paper indicate that immunotherapy is effective in prolonging remission and survival in acute and chronic leukemia. The acute lymphocytic leukemias may or may not respond to immunotherapy and further work is needed in this area. No studies of immunotherapy in chronic lymphocytic leukemia have been done, but this will be an important area for investigation, since there is often profound immunodeficiency in this disease. The malignant lymphomas are another fertile area for this type of research, since they have a high response rate, tumor associated immunodeficiency, and at least differentiation antigens if not tumor specific antigens. The scientific basis for the use of immunotherapy in leukemia includes the demonstration of a relationship of rate and duration of remission and survival to immunocompetence, the demonstration of unique tumor associated antigens on leukemia cells, and the demonstration of immune responses to these antigens which can be boosted by immunization. At the present time, active nonspecific immunotherapy with BCG and MER and active specific immunotherapy have been proved effective in acute myelogenous leukemia. Careful attention should be given to dose schedule, route, and so forth. Other types of immunotherapy remain to be explored.

AB - The data reviewed in this paper indicate that immunotherapy is effective in prolonging remission and survival in acute and chronic leukemia. The acute lymphocytic leukemias may or may not respond to immunotherapy and further work is needed in this area. No studies of immunotherapy in chronic lymphocytic leukemia have been done, but this will be an important area for investigation, since there is often profound immunodeficiency in this disease. The malignant lymphomas are another fertile area for this type of research, since they have a high response rate, tumor associated immunodeficiency, and at least differentiation antigens if not tumor specific antigens. The scientific basis for the use of immunotherapy in leukemia includes the demonstration of a relationship of rate and duration of remission and survival to immunocompetence, the demonstration of unique tumor associated antigens on leukemia cells, and the demonstration of immune responses to these antigens which can be boosted by immunization. At the present time, active nonspecific immunotherapy with BCG and MER and active specific immunotherapy have been proved effective in acute myelogenous leukemia. Careful attention should be given to dose schedule, route, and so forth. Other types of immunotherapy remain to be explored.

UR - http://www.scopus.com/inward/record.url?scp=0017149256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017149256&partnerID=8YFLogxK

M3 - Article

C2 - 781412

AN - SCOPUS:0017149256

VL - 60

SP - 1019

EP - 1042

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 5

ER -